Back to top
more

Adaptimmune Therapeutics (ADAP)

(Real Time Quote from BATS)

$1.08 USD

1.08
1,038,970

+0.02 (1.89%)

Updated Apr 26, 2024 02:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Fiscal Year End for Adaptimmune Therapeutics PLC falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 147 205 370 368 90
Receivables 1 7 1 0 0
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 60 43 45 30 31
Total Current Assets 208 255 415 398 120
Net Property & Equipment 51 54 30 28 31
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 3
Deferred Charges 0 0 0 0 0
Intangibles 0 0 1 2 2
Deposits & Other Assets 3 2 2 5 5
Total Assets 283 329 470 451 182
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 8 5 8 6 6
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 30 31 30 27 23
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 29 26 22 3 2
Total Current Liabilities 73 65 63 39 34
Mortgages 0 0 0 0 0
Deferred Taxes/Income 149 161 177 49 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 1 1 1 1 1
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 243 247 264 110 58
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 2 1 1 1 1
Capital Surplus 1,065 991 960 936 586
Retained Earnings -1,023 -909 -744 -586 -456
Other Equity -4 -1 -11 -10 -7
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 40 82 206 341 124
Total Liabilities & Shareholder's Equity 283 329 470 451 182
Total Common Equity 40 82 206 341 124
Shares Outstanding 994.20 164.50 156.20 154.70 105.10
Book Value Per Share 0.04 0.50 1.32 2.21 1.18

Fiscal Year End for Adaptimmune Therapeutics PLC falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 147 162 205 166
Receivables NA 1 1 3 2
Notes Receivable NA 0 0 0 0
Inventories NA 0 0 0 0
Other Current Assets NA 60 57 54 46
Total Current Assets NA 208 219 262 214
Net Property & Equipment NA 51 53 55 54
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 0 0 0 0
Deposits & Other Assets NA 3 3 3 2
Total Assets NA 283 297 343 288
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 8 14 15 5
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 30 27 25 33
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 29 29 31 22
Total Current Liabilities NA 73 75 76 64
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 149 111 117 119
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 1 1 1
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 243 209 216 204
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 2 2 2 1
Capital Surplus NA 1,065 1,061 1,058 993
Retained Earnings NA -1,023 -975 -930 -908
Other Equity NA -4 0 -3 -2
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 40 88 127 84
Total Liabilities & Shareholder's Equity NA 283 297 343 288
Total Common Equity 0 40 88 127 84
Shares Outstanding 994.20 994.20 994.20 994.20 154.60
Book Value Per Share 0.00 0.04 0.09 0.13 0.54